Result of General Meeting

RNS Number : 9494K

Avacta Group PLC

05 August 2013

 



THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, NEW ZEALAND, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR ANY JURISDICTION IN WHICH SUCH PUBLICATION OR DISTRIBUTION IS PROHIBITED. 

Press Release

5 August 2013

Avacta Group plc

("Avacta" or "the Company")

Result of General Meeting

Avacta Group plc (AIM: AVCT), a global provider of innovative diagnostic tools, consumables and reagents aimed at reducing the cost of human and animal healthcare, is pleased to announce that the resolutions put to shareholders at today's General Meeting in connection with the Placing announced by the Company on 18 July 2013, were duly passed.

Following the passing of the resolutions at the General Meeting, 854,545,457 new Ordinary Shares have been allotted to existing and new investors, conditional upon the admission of such Ordinary Shares to trading on AIM. It is expected that settlement will occur, admission to trading on AIM will become effective and dealings will commence in respect of the 854,545,457 new Ordinary Shares at 8.00am on 6 August 2013. Upon admission, the new Ordinary Shares will be issued, credited as fully paid and will rank pari passu in all respects with the existing Ordinary Shares of the Company.

Following admission of the 854,545,457 new Ordinary Shares to trading on AIM, the total number of Ordinary Shares with voting rights in issue will be 4,011,890,369 and this figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.

- Ends -

Enquiries:

Avacta Group plc Alastair Smith, Chief Executive Officer Tim Sykes, Chief Financial Officer	Tel:  [phone] www.avacta.com
Numis Securities Limited     Michael Meade / Freddie Barnfield - Nominated Adviser James Black - Corporate Broking	Tel:  [phone] www.numiscorp.com
Media Enquiries Abchurch Communications Joanne Shears / Jamie Hooper / Harriet Rae [e-mail]	Tel: [phone] www.abchurch-group.com

Important Notice:

This announcement has been prepared solely to provide information about the Placing and it does not constitute, or form part of, any offer or invitation to purchase, underwrite or otherwise acquire Ordinary Shares, or the solicitation of any such offer. Without limiting the foregoing statement, this announcement does not constitute an offer of Ordinary Shares for sale in the United States. The Ordinary Shares have not been and will not be registered under the United States Securities Act of 1933, as amended (the Securities Act), or the laws of any state, and may not be offered or sold within the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state laws. Avacta Group plc does not intend to register the Ordinary Shares under the Securities Act. No public offering of Ordinary Shares will be made in the United States.

Notes to Editors:

Avacta Group plc is a global provider of innovative technologies, consumables and reagents for the life science markets, from drug discovery to diagnostics.

Avacta's products address one of the most significant global challenges facing mankind today - the rapidly rising cost of healthcare for a growing and ageing population.

The cost of healthcare is driven by many factors.  New drugs are expensive to develop, most don't reach the patient and those that do are often very costly to prescribe.  Inadequate, incorrect or slow diagnosis causes delays that lead to longer or less effective courses of treatment resulting in lengthy or repeated hospitalisation.

Avacta is dedicated to developing and providing innovative and practical tools to help drug developers get their products to market quicker and more reliably, and to providing clinicians with rapid and powerful diagnostics to improve patient treatment, helping to reduce the cost of healthcare worldwide.

Avacta joined AIM in August 2006 and is based in Wetherby, England.

For further information visit www.avacta.com

 

END

 

 

ROMUVVKRONAWRRR